---
document_datetime: 2026-02-11 13:52:08
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/sephience-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: sephience-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.178538
conversion_datetime: 2026-02-13 18:47:04.528857
docling_version:
  docling-serve: 1.12.0
  docling-jobkit: 1.10.2
  docling: 2.73.1
  docling-core: 2.65.1
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Sephience

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope   | Opinio n/   | Commi ssion   | Product Inform Summary   |
|----------------------|---------|-------------|---------------|--------------------------|

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | on          | amend ed on   |     |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|---------------|-----|
| EMA/PAM/0000295271                    | Final report for study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 11/12/ 2025 |               | n/a |
| Variation type IB / EMA/VR/0000294325 | This was an application for a group of variations. B.I.a.1 Change in the manufacturer of a starting material/reagent/intermedia te used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.a The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer - Accepted B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.z Other variation - Accepted B.I.a.1 Change in the | 03/12/ 2025 |               |     |

<div style=\"page-break-after: always\"></div>

| manufacturer of a starting material/reagent/intermedia te used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.a The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer - Accepted B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process of the active substance - Accepted B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process of the active substance - Accepted B.I.a.1 Change in the   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| manufacturer of a starting material/reagent/intermedia te used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.z Other variation - Accepted B.I.a.1 Change in the manufacturer of a starting material/reagent/intermedia te used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.f Changes to quality control testing arrangements for the active substance-replacement or addition of a site where   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| batch control/testing takes place - Accepted B.I.a.1 Change in the manufacturer of a starting material/reagent/intermedia te used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.f Changes to quality control testing arrangements for the active substance-replacement or addition of a site where batch control/testing takes place - Accepted B.I.a.1 Change in the manufacturer of a starting material/reagent/intermedia te used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance,   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                                        |                                                                                                                                             |             |                        | where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.f Changes to quality control testing arrangements for the active substance-replacement or addition of a site where batch control/testing takes place - Accepted   |
|----------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|-------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/00002902 44 | B.II.f.1.b Extension of the shelf life of the finished product - B.II.f.1.b.1 As packaged for sale (supported by real time data) - Accepted | 28/08/ 2025 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                          |